Uptick Staff have been on the hunt this week for strong companies to feature, keeping our investor readership in mind, we’ve found another one. Islet Sciences, Inc. Read up below, the company won’t disappoint.
Former American Diabetes Association Executive Chairman and Eli Lilly Executive Joins Islet Sciences as Chairman, President and CEO
Larry K. Ellingson, Proven Pharmacy Executive, Adds Significant Diabetes and Public Company Expertise.
RALEIGH, NC — (UPTICK Newswire – October 2, 2015) — Islet Sciences, Inc. (ISLT) (“Islet Sciences”), a biopharmaceutical company focused on developing new medicines and technologies for the treatment of metabolic disease, today announced that Larry K. Ellingson, a pharmaceutical industry veteran, has joined Islet as Chairman, President and Chief Executive Officer, effective September 24, 2015.
Mr. Ellingson brings significant experience with publicly traded and private pharmaceutical and life science companies, having started his career with Eli Lily & Company in 1971, retiring 30 years later as Executive Director Professional Relations & Advocacy for Diabetes Care Worldwide. Mr. Ellingson also served as a member of the Executive Committee and Chair of the Board of the American Diabetes Association (ADA) for three years. He currently sits on the Board of the National Diabetes Volunteer Leadership Council and on the Scientific Advisory Board of CHD Bioscience, a private company headquartered in Fort Collins, Colo. He is a Member of the European Association for the Study of Diabetes and a Life Member of the International Diabetes Federation.
John Steel, founder of Islet Sciences, commented, “We are honored to name a proven leader in pharmaceutical sales and development like Larry Ellingson to lead Islet, and firmly believe that his expertise, industry relationships and strong work ethic make him the ideal person to take Islet to the next level.”
Mr. Ellingson added, “Islet Sciences’ mission is to change the way we treat Diabetes, and this is a goal I have pursued most of my professional career. Islet’s current pipeline includes compelling immune modulating candidates, a cell therapy based artificial pancreas, and an exciting biomarker for the early detection of the onset of type 1 diabetes or insulin dependent type 2 diabetes. I look forward to advancing these candidates, pursuing commercialization and developing lasting shareholder value while ultimately contributing to the eradication of this terrible disease.”
About Islet Sciences
Islet Sciences, Inc., a biopharmaceutical company based in Raleigh, NC, is developing new medicines and technologies for the treatment of metabolic disease. For more information, please visithttp://www.isletsciences.com.
Certain statements in this press release constitute forward-looking statements. These statements are not historical facts but instead represent only Islet Science’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside Islet Science’s control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. Factors that could affect Islet Science’s financial and other results are included in Islet Science’s periodic filings with the SEC pursuant to the Securities Exchange Act of 1934.
Brett Maas, Managing Partner, Hayden IR
SOURCE: Islet Sciences, Inc.